Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins Licenses Preeclampsia Biomarkers from Mount Sinai

NEW YORK (GenomeWeb News) – Miraculins has licensed from Mount Sinai Hospital the rights to commercialize a portfolio of biomarkers for use in developing diagnostic assays for early detection of preeclampsia, the Winnipeg, Canada-based firm said today.
The firm said that there is currently no reliable test to accurately predict preeclampsia, which can cause high blood pressure and the buildup of protein in the urine of pregnant women. Miraculins said that a biomarker-based test could be used as a general screen for all pregnant women, representing a market of 6.4 million women annually in the US alone.
Under terms of the deal, Miraculins will issue 310,000 chares of its common stock to Mount Sinai as an up-front payment. The firm’s shares trade on the TSX Venture Exchange in Canada, and in Wednesday afternoon trade were down 44 percent at Cdn$.05 per share.
Miraculins will make additional commercial and developmental milestone payments to Mount Sinai. An annual maintenance fee would also be payable, commencing on the third anniversary of the signing of this agreement. Miraculins also will make annual minimum and running royalties on sales after any tests are commercialized.
The partners will conduct some of the development activities jointly, while Miraculins is responsible for sales of the products.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.